logo-loader
Avacta Group PLC

Avacta's Alastair Smith encouraged by significant progress and share price momentum

Alastair Smith, chief executive of Avacta Group PLC (LON:AVCT), caught up with Proactive London's Andrew Scott to talk through a business update released from the firm to coincide with its annual general meeting this week.

Among recent highlights were the partnership with LG Chem, which sent the company’s shares soaring in December, and the research collaboration with leading scientists at Tufts University Medical School.

The company also announced a licensing deal last year with New England Biolabs and appointed Jose Saro as the chief medical officer.

Quick facts: Avacta Group PLC

Price: £0.21

Market: AIM
Market Cap: £24.39 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Avacta Plc's therapeutics business 'has huge amount of potential' - analyst...

Capital Network analyst Ed Stacey discusses the major value driver for Avacta - the development of its proprietary Affimer technology for therapeutics, particularly in the immune-oncology (I-O) space. The group's reported interim results to January 2019 today, revealing revenues of...

on 9/4/19

2 min read